

Speaker Bios

Dr. Jacqueline French

Professor of Neurology in the Comprehensive Epilepsy Center at NYU Langone School of Medicine and Founder/Director of the Epilepsy Study Consortium



Dr. Jacqueline French is a professor of Neurology in the Comprehensive Epilepsy Center at NYU Langone School of Medicine and Founder/Director of the Epilepsy Study Consortium, an academic group that has performed a number of early phase clinical trials in epilepsy, and has developed new methodologies for epilepsy trials. Dr. French trained in Neurology at Mount Sinai Hospital in New York and did her fellowship training in EEG and epilepsy at Mount Sinai Hospital and Yale University.

Dr. French has focused her research efforts on the development of new therapeutics for epilepsy, and new methodologies for clinical trials. Over the past 20 years she has served as the Principle investigator on a number of trials for new epilepsy drugs. She is responsible for the creation of a number of new trial designs that have been accepted by regulatory authorities for new drug approval. Dr. French has been active in creating guidelines for the American Academy of Neurology and the International League Against Epilepsy. She chaired an AAN/AES committee that produced two widely quoted guidelines on the use of new antiepileptic drugs. She has served as chair of the International League Against Epilepsy North American Regional Commission, and Commission on Therapeutic strategies. Dr. French serves as the Chief Medical/Innovation Officer of the Epilepsy Foundation. She is the past president of the American Epilepsy Society. She is the past Secretary of the American Society of Experimental Neurotherapeutics. She is the recipient of the American Epilepsy Society Lennox Award (2017) and Service Award (2005), the Epilepsy Foundation Hero award (2013), and is an ILAE Ambassador for Epilepsy. She has authored over 300 articles and chapters, is the editor of three books, and lectures internationally on clinical trials and the use of antiepileptic drugs.

Dr. Michael Rogawski

Professor in the Department of Neurology with joint appointment in the Department of Pharmacology, and an affiliate member of the Center for Neuroscience at the University of California, Davis



Dr. Michael A. Rogawski is a professor of neurology and pharmacology at the University of California Davis and an internationally recognized expert on drug discovery and development for epilepsy. His research encompasses laboratory studies as well as clinical trials in post-traumatic epilepsy. Studies conducted by Dr. Rogawski on AMPA receptors and neurosteroids have led to new treatment approaches for seizures and epilepsy, and the marketed treatment for postpartum depression brexanolone (Zulresso™). Dr. Rogawski has authored more than 275 research papers, reviews, and book chapters, and edited five books. He received the NIH Director's Award; the Epilepsy Research Award for Outstanding Contributions to the Pharmacology of Antiepileptic Drugs from the American Society for Pharmacology and Experimental Therapeutics; and the American Academy of

Neurology Neuroendocrine Research Award. He is an elected fellow of the American Association for the Advancement of Science, and in 2019 received the UC David Chancellor's Innovator of the Year Award.

Dr. Rogawski graduated from Amherst College with a B.A. in biophysics and from Yale University with an M.D. and Ph.D. in pharmacology. He completed postdoctoral training in the Laboratory of Neurophysiology at the National Institute of Neurological Disorders and Stroke and residency training in neurology at Johns Hopkins. Until 2006, he was senior investigator and chief of the Epilepsy Research Section at NINDS and subsequently was appointed chair of the Department of Neurology at UC Davis. He has served on the board of directors of the American Epilepsy Society and as an advisor to the NIH and the U.S. Food and Drug Administration. He is past president of the American Society for Experimental Neurotherapeutics.

Ian Mortimer, *President and CEO, Xenon Pharmaceuticals Inc.*



Ian Mortimer has served as Xenon's President and Chief Executive Officer since June 2021, previously serving as President and Chief Financial Officer since March 2018. Mr. Mortimer previously served as Corporate Secretary from June 2015 to March 2021, as Chief Financial Officer and Chief Operating Officer since March 2015 and as Chief Financial Officer since October 2013. Prior to joining Xenon, Mr. Mortimer served as Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation (now Arbutus Biopharma Corporation), a Nasdaq-listed biotechnology company, from 2007 until October 2013. Mr. Mortimer was responsible for all aspects of Tekmira's finance and capital markets activities and led Tekmira's listing on Nasdaq in 2010. From 2004 to 2007, Mr. Mortimer was Chief Financial Officer at Inex Pharmaceuticals and held various other positions at Inex Pharmaceuticals from 1997 to 2004. Since July 2020, Mr. Mortimer has served on the board of directors of Perimeter Medical Imaging AI, Inc., a publicly-traded medical device company focused on advanced in procedural medical imaging tools. Since November 2017, Mr. Mortimer has served on the board of directors of Appili Therapeutics, Inc., a publicly-traded biopharmaceutical company focused on developing treatments for infectious diseases. Mr. Mortimer has an M.B.A. from Queen's University, a B.Sc. in Microbiology from the University of British Columbia and is a Chartered Professional Accountant, Certified Management Accountant.

Dr. Simon Pimstone, *Executive Chair of the Board, Xenon Pharmaceuticals Inc.*



Dr. Pimstone has served as Executive Chair of Xenon's Board since June 2021 and as a Board member since November 1996, as Chief Executive Officer from January 2003 to June 2021, and as Xenon's President from January 2003 to March 2018. Since 2012, Dr. Pimstone has been a Consultant Physician at the University of British Columbia Hospital, Cardiology Clinic, and since 2014, he has held the position of Clinical Associate Professor at the University of British Columbia, Division of General Internal Medicine. Currently, Dr. Pimstone is an Investigator at the Centre for Heart Lung Innovation (HLI) research centre. Dr. Pimstone currently serves as chair of the board of Eupraxia Pharmaceuticals Inc., (TMX: EPRX) a specialty biotechnology company (publicly-traded since March 2021), Alpha-9 Theranostics Inc., a private radiopharmaceutical company, where he has served as a director since May 2020 as well as XYON Health Inc., a private digital health company, where he has served as a director since 2019. Dr. Pimstone holds an MBChB from the University of Cape Town, a FRCPC from the University of British Columbia, and a Ph.D. from the University of Amsterdam in cardiovascular genetics. Previously, Dr. Pimstone was director and chair of the board of directors of LifeSciences British Columbia, a non-profit industry association that supports the life science community, and a former director of the Providence Healthcare Research Trust, BC Advantage Life Sciences Fund, Centre for Molecular Medicine and Therapeutics, BIOTECANADA, and BC Health Research Strategy Advisory Board of the Michael Smith Foundation for Health Research.

Dr. Chris Von Seggern, *Chief Commercial Officer, Xenon Pharmaceuticals Inc.*



Dr. Von Seggern has served as Xenon's Chief Commercial Officer since August 2020. Most recently, prior to joining Xenon, Dr. Von Seggern was a Partner at ClearView Healthcare Partners from 2011 to 2019, where he developed broad experience overseeing a range of commercial engagements involving multiple therapeutic areas as well as strategic due diligence on in-licensing and M&A opportunities. Through his tenure from 2008 to 2019 at ClearView, Dr. Von Seggern worked across the pharmaceutical sector with emphasis in orphan diseases and transformational technologies. From 2006 to 2008, Dr. Von Seggern served as a Consultant for Leerink Swann Strategic Advisors. Dr. Von Seggern began his career at the National Institutes of Health where he served as an AAAS Science Policy Fellow within the National Institute of Diabetes, Digestive, and Kidney Diseases from 2005 to 2006. While at the NIDDK, Dr. Von Seggern helped set strategic direction for the Institute focusing on diabetes research and translational medicine. Dr. Von Seggern received his Ph.D. in pharmacology and molecular sciences as well as his Master of Public Health from Johns Hopkins University School of Medicine. Dr. Von Seggern received his MBA from Northeastern University and he earned his B.S. in biochemistry and molecular biology from the Pennsylvania State University.